Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

This study has been terminated.

Study NCT00055432 Information provided by Eli Lilly and Company

First Received: March 3, 2003 Last Updated: September 13, 2006 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given